1. The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists
- Author
-
Prabhu S. Parimi, Kimmie K. McLaurin, Shelagh M. Szabo, Joseph B. Domachowske, Pierre C. Wong, William V. La Via, Michael Marcus, Deborah M. Friedman, Iqra Syed, Daniel F. Garcia, and Veena R. Kumar
- Subjects
Male ,Palivizumab ,medicine.medical_specialty ,Pediatrics ,palivizumab ,Respiratory Syncytial Virus Infections ,Antiviral Agents ,03 medical and health sciences ,0302 clinical medicine ,030225 pediatrics ,medicine ,Humans ,neonatologist ,030212 general & internal medicine ,Neonatology ,Practice Patterns, Physicians' ,pulmonologist ,Pulmonologists ,cardiologist ,business.industry ,RSV ,Articles ,pediatrician ,United States ,Preventive therapy ,Health Care Surveys ,Respiratory Syncytial Virus, Human ,Pediatrics, Perinatology and Child Health ,Emergency medicine ,Female ,Immunization ,Disease prevention ,business ,medicine.drug - Abstract
This study was conducted to survey US pediatric specialists about administration of respiratory syncytial virus (RSV) immunoprophylaxis, communication patterns among physicians and parents, and barriers to access. Separate surveys were sent to neonatologists, pediatricians, pediatric pulmonologists, and pediatric cardiologists. Most physicians (≥93.5%) routinely recommended immunoprophylaxis to high-risk children. Most respondents (≥71.8%) reported that >50.0% of eligible infants and young children received each monthly dose throughout the RSV season, with the first dose most commonly administered before discharge from the birth hospitalization. To ensure receipt of subsequent doses, specialists frequently scheduled a follow-up visit at the end of the current appointment. All specialists reported insurance denials as the biggest obstacle to the administration of immunoprophylaxis to high-risk children. These findings may be used to improve adherence to immunoprophylaxis by enhancing education and physician-parent communications about severe RSV disease prevention, and by reducing known barriers to use of this preventive therapy.
- Published
- 2016
- Full Text
- View/download PDF